Balance Sheet: Assets
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Moderna Inc., consolidated balance sheet: assets
US$ in millions
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
The financial data reveals several notable trends over the analyzed period. Total assets showed strong growth from 2019 through 2022, increasing from US$1,589 million to US$25,858 million, before decreasing to US$18,426 million in 2023. This reflects significant expansion followed by a contraction in the most recent year.
Within current assets, there was substantial growth from US$1,129 million in 2019 to a peak of US$16,071 million in 2021. However, current assets declined to US$10,325 million by the end of 2023. Key components such as cash and cash equivalents exhibited a sharp increase through 2021, rising from US$236 million to US$6,848 million, then declined to US$2,907 million in 2023. Investments followed a similar pattern, growing markedly through 2022 before decreasing to US$5,697 million in 2023.
Accounts receivable surged significantly between 2019 and 2021, from US$5 million to US$3,175 million, then fell to US$892 million by 2023. Inventory fluctuated, peaking at US$1,441 million in 2021 before falling to US$202 million in 2023, suggesting possible changes in supply chain or sales volume. Prepaid expenses and other current assets increased steadily to US$1,195 million in 2022, then dropped to US$627 million.
Non-current assets displayed strong growth reaching US$12,427 million in 2022, driven largely by investments, property, plant and equipment (PP&E), and other non-current assets, before declining to US$8,101 million in 2023. Investments, non-current rose markedly from US$160 million in 2019 to US$8,318 million in 2022, then decreased to US$4,677 million in 2023. PP&E increased from US$201 million in 2019 to US$2,018 million in 2022, slightly decreasing afterward. The right-of-use assets category showed an irregular pattern with a notable increase to US$713 million in 2023 after being relatively stable in prior years.
Other categories such as deferred tax assets experienced a significant increase peaking at US$982 million in 2022, but then sharply declined to US$81 million in 2023. New categories appeared during the period, including goodwill and intangible assets valued modestly in 2023, suggesting recent acquisitions or capitalized expenses.
Overall, the data depicts rapid asset growth primarily during 2020 and 2021, driven by increases in cash, investments, and receivables, reflecting strong operational expansion or liquidity accumulation. The subsequent declines in 2022 and 2023 across many asset categories point to asset base rationalization, possible divestitures, or reduction in working capital. This pattern may indicate a phase of financial consolidation or repositioning after a period of aggressive growth.